{"prompt": "['056-F275, Clinical Investigation Plan Template, Version 2.0', 'Page 6 of 115', '2.0', 'Section 21.3: Removed', 'Typo', 'Dana Wigert, Sr. Prin. Clinical', 'Ltd reference.', 'Research Specialist', 'Fred Kueffer, Pr. Statistician', '3.0', 'Section 18.3.2: Revised', 'Typo', 'Dana Wigert, Sr. Prin. Clinical', 'primary safety hypothesis', 'Research Specialist', 'statement and endpoint', 'Fred Kueffer, Pr. Statistician', 'definition', '4.0', 'Sections 5, 8 and 18.2:', 'FDA feedback', 'Dana Wigert, Sr. Prin. Clinical', 'Included additional details', 'Research Specialist', 'about the sample size in', 'Fred Kueffer, Pr. Statistician', 'relation to Japanese data', 'and how Japanese data will', 'be reported', 'Version 4, 10NOVO016', 'Confidential']['056-F275, Clinical Investigation Plan Template, Version 2.0', 'Page 7 of 115', 'Table of Contents', '1.', 'Version History', '3', 'Table of Contents', '7', '2.', 'Glossary', '11', '3.', 'Sponsor Contacts', '14', '4.', 'CROs/Core Laboratories', '15', '5.', 'Synopsis', '15', '6.', 'Introduction', '19', '6.1. Background', '19', '6.2. Purpose', '22', '7.', 'Objectives and Enpoints', '23', '7.1.', 'Objectives', '23', '7.1.1.', 'Primary Objectives', '23', '7.1.1.1.', 'Primary Efficacy Objective', '23', '7.1.1.2.', 'Primary Safety Objective', '23', '7.1.2.', 'Secondary Objective', '23', '7.1.3.', 'Ancillary Objectives', '23', '7.2. Enppoints', '24', '7.2.1.', 'Primary Enpoints', '24', '7.2.2.', 'Secondary Endpoint', '25', '7.2.3.', 'Ancillary Enppoints', '25', '8.', 'Study Design', '26', '8.1. Duration', '27', '8.2.', 'Rationale', '28', '9.', 'Product Description', '28', '9.1. General', '28', '9.1.1.', 'Arctic Front Advance Cardiac CryoAblation Catheters', '29', '9.1.2.', 'Freezor MAX Cardiac CryoAblation Catheters', '29', '9.1.3.', 'FlexCath Advance Steerable Sheath', '29', '9.1.4.', 'Achieve Mapping Catheter', '30', '9.1.5.', 'CryoConsole', '30', '9.1.6.', 'Coaxial Umbilical', '30', '9.1.7.', 'Electrical Umbilical', '30', '9.1.8.', 'Manual Retraction Kit', '30', '9.1.9.', '30', '9.1.10.', 'Additional Study Devices', '31', '9.2. Packaging', '31', '9.3.', 'Product Receipt, Tracking and Storage', '31', 'Version 4, 10NOVO016', 'Confidential']['056-F275, Clinical Investigation Plan Template, Version 2.0', 'Page 8 of 115', '10.', 'nvestigator/Investigational Center Selection', '32', '11.', 'Center Activation', '32', '12.', 'Selection of Subjects', '33', '12.1.', 'Study Population', '33', '12.2.', 'Subject Enrollment', '33', '12.3.', 'Inclusion Criteria', '33', '12.4.', 'Exclusion Criteria', '34', '13.', 'Minimization of Bias', '34', '14.', 'Study Procedures', '35', '14.1.', 'Schedule of Events', '35', '14.2.', 'Role of the Sponsor', '37', '14.3.', 'Subject Consent', '37', '14.4.', 'Enrollment, Baseline and Pre-ablation', '39', '14.5.', 'Procedure', '40', '14.5.1.', 'Esophageal Visualization and Temperature Monitoring', '40', '14.5.2.', 'Peri-procedural Anticoagulation', '40', '14.5.3.', 'Diaphragm Movement', '40', '14.5.4.', 'Balloon Pulmonary Vein (PV) Cryoablation', '41', '14.5.5.', 'Other Ablations during Index Procedure', '41', '14.5.6.', 'Cardioversion', '41', '14.5.7.', 'Procedure Documentation', '41', '14.6.', 'Hospital Discharge', '42', '14.7.', 'Medications', '42', '14.7.1.', 'Class I and III antiarrhythmic medication use after the 90 day post-procedure', 'blanking period', '43', '14.8.', 'Permissible Repeat Cryoablations', '43', '14.9.', 'Cardioversions', '43', '14.10.', 'Scheduled Follow-up Visits', '43', '14.10.1.', 'Six Week Phone Call', '45', '14.10.2.', 'Three Month Office Visit', '45', '14.10.3.', 'Six Month Office Visit', '45', '14.10.4.', 'Twelve Month Office Visit', '45', '14.11.', 'Unscheduled Office Visits', '45', '14.12.', 'Holter and TTM Management', '46', '14.13.', '12 lead Electrocardiograms', '46', '14.14.', '46', '14.15.', 'Assessment of Efficacy', '46', '14.16.', 'Assessment of Safety', '47', '14.17.', 'Recording Data', '47', '14.18.', 'Deviation Handling', '47', '14.19.', 'Subject Withdrawal or Discontinuation', '48', '15.', 'Risks and Benefits', '49', '15.1.', 'Potential Risks', '49', 'Version 4, 10NOVO016', 'Confidential']\n\n###\n\n", "completion": "END"}